MANDALMED, INC.
Biotech · Private
Allogeneic cell-based gene therapy delivering GALNS enzyme for mucopolysaccharidosis type IVA treatment
mandalmed.com →- Grants
- $4.8M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 2 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | $224,734 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | $808,592 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction Supplement | $2,001,205 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | $1,061,083 | |
| Federal grant | Department of Health and Human Services · Phase II · Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction Supplement | $131,530 | |
| Federal grant | Department of Health and Human Services · Phase I · Biologic Inhibitor of Galectin-3 for Liver Fibrosis | $299,900 | |
| Federal grant | Department of Health and Human Services · Phase I · Cell-based Gene Therapy for MPS IVA | $306,872 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1677 | Orphi Therapeutics Inc | — | — |
| 1678 | Myovant Sciences | — | — |
| 1679 | ROKE BIOTECHNOLOGIES LLC | — | — |
| 1680 | MANDALMED, INC. | — | — |
| 1681 | PSQUARE SCIENTIFIC, LLC | — | — |
| 1682 | Madison Vaccines Inc | — | $2.4M |
| 1683 | Canal Biosciences, Inc. | — | $2.3M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Preventing, Treating, And Reversing Liver Fibrosisapplication
- Proliferative Primary Human Sertoli Cell Cultures And Their Applicationsgranted
- GALECTIN-3C Combination Therapy For Human Cancergranted
- Methods And Compositions For Preventing, Treating, And Reversing Liver Fibrosisapplication
- Methods And Compositions For Preventing, Treating, And Reversing Liver Fibrosisapplication
- Sustained Release N-terminally Truncated GALECTIN-3 And Antibodies To GALECTIN-3 Carbohydrate Ligands For Use In Treating Cancerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.